Taikang Asset Management (Hong Kong) CO LTD Crinetics Pharmaceuticals, Inc. Transaction History
Taikang Asset Management (Hong Kong) CO LTD
- $715 Million
- Q1 2025
A detailed history of Taikang Asset Management (Hong Kong) CO LTD transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Taikang Asset Management (Hong Kong) CO LTD holds 8,500 shares of CRNX stock, worth $242,505. This represents 0.04% of its overall portfolio holdings.
Number of Shares
8,500
Previous 8,500
-0.0%
Holding current value
$242,505
Previous $434,000
34.33%
% of portfolio
0.04%
Previous 0.07%
Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
233Shares Held
87.1MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$266 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$197 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$178 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$178 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$146 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.53B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...